References
- Riccio AM, Saverino D, Pesce G et al. Effects of different up-dosing regimens for hymenoptera venom immunotherapy on serum CTLA-4 and IL-10. PLoS ONE 7(6), e37980 (2012).
- Ciprandi G, Contini P, Pistorio A, Murdaca G, Puppo F. Sublingual immunotherapy reduces soluble HLA-G and HLA-A,-B,-C serum levels in patients with allergic rhinitis. Int. Immunopharmacol. 9(2), 253–257 (2009).
- To Y, Ito K, Kizawa Y et al. Targeting phosphoinositide-3-kinase- δ with theophylline reverses corticosteroid insensitivity in COPD. Am. J. Resp. Crit. Care Med. 182, 897–904 (2010).
- Kobayashi Y, Wada H, Rossios C et al. A novel macrolide solithromycin exerts superior anti-inflammatory effect via NF-kB. J. Pharmacol. Exp. Ther. 345, 76–84 (2013).
- Cox G, Thomson NC, Rubin AS et al.; AIR Trial Study Group. Asthma control during the year after bronchial thermoplasty. N. Engl J. Med. 356(13), 1327–1337 (2007).
- Pavord ID, Cox G, Thomson NC et al.; RISA Trial Study Group. Safety and efficacy of bronchial thermoplasty in symptomatic, severe asthma. Am. J. Respir. Crit. Care Med. 176(12), 1185–1191 (2007).
- Castro M, Rubin AS, Laviolette M et al.; AIR2 Trial Study Group. Effectiveness and safety of bronchial thermoplasty in the treatment of severe asthma: a multicenter, randomized, double-blind, sham-controlled clinical trial. Am. J. Respir. Crit. Care Med.181(2), 116–124. (2010).
- Pelaia G, Vatrella A, Maselli R. The potential of biologics for the treatment of asthma. Nat. Rev. Drug Discov. 11(12), 958–972 (2012).
- Pavord ID, Korn S, Howarth P et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 380(9842), 651–659 (2012).
- Corren J, Lemanske RF, Hanania NA et al. Lebrikizumab treatment in adults with asthma. N. Engl J. Med. 365(12), 1088–1098 (2011).
- Wenzel S, Ford L, Pearlman D et al. Dupilumab in persistent asthma with elevated eosinophil levels. N. Engl J. Med. 368(26), 2455–2466 (2013).
- Vultaggio A, Maggi E, Matucci A. Immediate adverse reactions to biologicals: from pathogenic mechanisms to prophylactic management. Curr. Opin. Allergy Clin. Immunol. 11(3), 262–268 (2011).
- Senti G, Prinz Vavricka BM, Erdmann I et al. Intralymphatic allergen administration renders specific immunotherapy faster and safer: a randomized controlled trial. Proc. Natl Acad. Sci. USA. 105(46), 17908–17912 (2008).
- Senti G, Graf N, Haug S, Rüedi N et al. Epicutaneous allergen administration as a novel method of allergen-specific immunotherapy. J. Allergy Clin. Immunol. 124(5), 997–1002 (2009).
- Kündig TM, Senti G, Schnetzler G et al. Der p 1 peptide on virus-like particles is safe and highly immunogenic in healthy adults. J. Allergy Clin. Immunol. 117(6), 1470–1476 (2006).
- Kim EH, Bird JA, Kulis M et al. Sublingual immunotherapy for peanut allergy: clinical and immunologic evidence of desensitization. J. Allergy Clin. Immunol. 127(3), 640–646 (2011).
- Fernández-Rivas M, Garrido Fernández S, Nadal JA et al. Randomized double-blind, placebo-controlled trial of sublingual immunotherapy with a Pru p 3 quantified peach extract. Allergy 64(6), 876–883 (2009).
- Nadeau KC, Schneider LC, Hoyte L et al. Rapid oral desensitization in combination with omalizumab therapy in patients with cow’s milk allergy. J. Allergy Clin. Immunol. 127(6), 1622–1624 (2011).